Highlights
– Discontinuation of GLP‑1 receptor agonists (GLP‑1RAs) before or in early pregnancy was associated with a mean 3.3‑kg greater gestational weight gain compared with propensity‑matched unexposed pregnancies.
– Exposed pregnancies had higher risks of excess gestational weight gain (65% vs 49%), preterm delivery (17% vs 13%), gestational diabetes (20% vs 15%), and hypertensive disorders of pregnancy (46% vs 36%).
